Home › Alzheimer's Disease › NCT03821857
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RecruitingPhase 4Healthy volunteers welcome
Who can join
Ages 60 and older · Women · Healthy volunteers welcome
Full eligibility criteria
Mayo Clinic Rochester- Inclusion Criteria: * Women who previously participated in this study * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation Mayo Clinic Jacksonville- Inclusion Criteria: * African American Women * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation
About the study
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
What is being tested
- 18-F-Flortaucipir (drug)
Sponsor: Mayo Clinic · Participants: 614 · Started: Jun 27, 2019
Contact the study team
- June Kendall-Thomas, CRC · Phone: 507-293-9397
- Desirae Howe-Clayton, CRC · Phone: 507-255-0111
Official record on ClinicalTrials.gov — NCT03821857
Locations in the U.S.
| Florida | Mayo Clinic, Jacksonville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.